Posted: June 4, 2018 June 4, 2018 Elizabeth Alvarez, Updated: 8:45 AM San Diego students launch school shooting safety PSA Categories: Good Morning San Diego, Local San Diego News FacebookTwitter 00:00 00:00 spaceplay / pause qunload | stop ffullscreenshift + ←→slower / faster ↑↓volume mmute ←→seek . seek to previous 12… 6 seek to 10%, 20% … 60% XColor SettingsAaAaAaAaTextBackgroundOpacity SettingsTextOpaqueSemi-TransparentBackgroundSemi-TransparentOpaqueTransparentFont SettingsSize||TypeSerif MonospaceSerifSans Serif MonospaceSans SerifCasualCursiveSmallCapsResetSave SettingsMonday, San Diego Unified students, in partnership with San Diego Unified School Police and Crime Stoppers San Diego, launched their “If You See Something, Say Something” Public Service Announcement Video Campaign. Elizabeth Alvarez live to get the details.The PSA titled, “If You See Something, Say Something,” produced by students from San Diego High School and Point Loma High School, was created as a call to action in response to the tragic school shootings that have taken place in the recent months.“Given the recent school shootings, both in Florida and Texas, we want to remind students and our community that their voice matters. We want to provide ways to report crime, in person or anonymously. Providing support for our school communities and creating safe learning environments is our top priority as a school police department. We are proud to partner with our students on this campaign and know this will add another layer of safety and security to our campuses,” said School Police Chief Mike Marquez.The campaign will target the entire San Diego County community with two 30-second PSAs produced in English and Spanish on television and online. Cox Communications has partnered with the students and San Diego Unified and will aireach PSA 200 times throughout June. Elizabeth Alvarez
Close A British government-backed review released on Thursday (14 May) is seeking billions of dollars to fund the development of 15 new antibiotics to counter antibiotic resistance.The review, led by former Goldman Sachs chief economist Jim ONeill, said the lump sum payments could add up to $16-$37bn (£10-23.5bn) over 10 years, but should only be made when companies have fully developed a successful bug-killing drug.Seen in a global context, and compared to the cost of inaction, its actually peanuts. Critically linked to that were also calling for an innovation fund, about $2bn perhaps over five years, that the pharmaceutical industry itself essentially finances, ONeill said.The review says that companies that develop new antibiotics should be awarded prize money of up to $3.5bn for each new drug, instead of selling the medication at a profit.Because if you come up with the specific incentives and rewards were suggesting to get them to produce more drugs, its essentially giving them a lot of financial relief. So we think its only right that they play a role in financing the research at the early stage, ONeill added.The prizes, of between $1.5bn and $3.5bn, should be funded in part by the pharma industry itself, ONeill said, probably also with input from national governments and the global taxpayer.I think the proposal were suggesting is better than what the pharma industry would like itself, which is much higher prices so they can just charge a lot more for it. I dont think that would be a better option for every individual in this country and elsewhere in the world, he said.The successful drugmaker would then be required to make no profit from its sales of the drugs to governments and healthcare providers around the world, ONeill added, saying this approach would de-link the profitability of a drug from its volume of sales.I think there are two core problems. Theres a demand problem and a supply problem. The paper weve published today focuses all about the supply issues of getting more drugs, he saidIn recent years, bugs resistant to multiple drugs have evolved at the same time as drugmakers have cut back investment in finding new ways to fight them, creating a global health threat as superbug strains of infections like tuberculosis and gonorrhoea have become untreatable.ONeill, who was asked last year by British Prime Minister David Cameron to take an economists view of the problem, said far too little is currently invested in hunting for new drugs against drug-resistant infections.In his initial report, ONeill estimated that anti-microbial resistance (AMR) could kill an extra 10 million people a year and cost up to $100tn by 2050 if it is not brought under control.ONeill has also proposed that a $2bn innovation fund financed by drug companies should be created to invest in early-stage research and speed up development of new medicines to fight drug-resistant superbugs.Sally Davies, the UK governments chief medical adviser, welcomed ONeills latest report, saying it would stimulate important conversations between governments, pharmaceutical companies and other funders.
Cognizant Technology Solutions, which carries out a major part of its global operations from India, has said that it may witness some losses due to uncertainty over continuation of $520 million contract with US-based healthcare services firm Health Net.Another US healthcare major Centene on Thursday said it had decided to buy Health Net in a cash and stock deal worth $6.3 billion. The acquisition is expected to be completed by early 2016.”The planned implementation of a seven-year master services agreement for end-to-end administrative services between Cognizant and Health Net, first announced in August 2014 and scheduled to begin in mid-2015, is being deferred while Health Net and Centene complete the merger review and approval process,” Cognizant said in a statement.Cognizant still remains positive about achieving its revenue guidance of $12.24 billion in 2015, despite seeing losses due to Centene’s acquisition of Health Net.”Despite the anticipated loss of approximately $100 million in incremental revenues during the second half of 2015, we are pleased to reaffirm our guidance for the year due to continued strong demand and projected over-performance in other parts of our business. Today’s announcement by Health Net will not impact our ability to achieve our goals for the year,” said Karen McLoughlin, Chief Financial Officer, Cognizant.Cognizant reported 20% growth in revenues for the first quarter ending March, while its top Indian rivals posted disappointing earnings during the same period.Cognizant recorded 9.7% increase in profit at $382.9 million during the quarter, strengthening the view that it remains insulated from the concerns that plague Indian firms such as Tata Consultancy Services (TCS) and Infosys.The company, which employs a major chunk of its global workforce of 211,700 in India, raised its revenue growth outlook for 2015 to 19.3%.
Vivo S1 launchChetan PriyadarshanIn this tech-savvy generation, the first thought while buying a phone is always confusing. What to focus more on the camera or the processor? With technology increasing at a lightning speed, the middle-class buyer can only imagine owning a smartphone packed with high-end specifications without burning a hole in the pocket.However, not all smartphone manufacturers quote a price to panic the consumers. Vivo is one such giant that pools features required to boast a well-designed phone sporting heavy technology and best camera with the launch of Vivo S1 in India today. The competitors are up for facing new challenges. Vivo S1 launchChetan PriyadarshanVivo S1 was launched in China in March and in Indonesia last month to great success in grabbing all the eyeballs with its latest MediaTek Helio P65 SoC, triple rear camera, 4,500mAh battery and an in-display fingerprint.The smartphone was launched in the Indian market today and made its tagline “It’s my style” come alive.Affordable smartphones driven by technology and premium specifications is something Vivo offers and with the S1 at Rs17,990 for 4GB/128GB configuration. The smartphone giant is making its presence felt among the mid-range smartphones arena. Vivo S1 launchChetan PriyadarshanThe other variants with 6GB/64GB and 6GB/128GB are priced at Rs18,990 and Rs 19,990, respectively.A 16-megapixel primary sensor, an 8-megapixel secondary sensor and a 2-megapixel tertiary sensor for the triple-rear camera allows you to capture memories as wide as your memory. The front is loaded with a 32-megapixel pop-up selfie camera and in-display fingerprint sensor sporting under a notched 6.83-inch full-HD+ Super AMOLED display.Vivo S1 is a competitive entrant in the Indian mid-range smartphone segment. It runs Funtouch OS9 based on Android 9.0 Pie out-of-the-box. The octa-core processor supported by the latest MediaTek Helio P65 SoC is backed by 4GB/6GB RAM variant and has up to 128GB storage. Vivo S1 launchedThe phone is a must to watch out for, so stay tuned for the upcoming full review.